Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.
Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.
The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.
The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.
According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).
According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.
Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial.
Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.
Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.
The findings from the phase II study of intermittent sunitinib in patients with previously untreated metastatic renal cell carcinoma demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.